| Bioactivity | Moxilubant (CGS-25019C;LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2–4 nM. Moxilubant can be used for cancer research[1]. |
| CAS | 146978-48-5 |
| Formula | C26H37N3O4 |
| Molar Mass | 455.59 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bhatt L, et al. Recent advances in clinical development of leukotriene B4 pathway drugs. Semin Immunol. 2017 Oct;33:65-73. |
Moxilubant
CAS: 146978-48-5 F: C26H37N3O4 W: 455.59
Moxilubant (CGS-25019C;LTB-019) is an orally active BLT1 antagonist which inhibits LTB4 signaling with a potency of 2–4
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.